ASCO 2024 | Overview of recent changes to the treatment landscape for HER2-positive CRC
John Strickler, MD, Duke University, Durham, NC discusses recent changes to the treatment landscape for HER2-positive colorectal cancer (CRC). The recent approval of trastuzumab deruxtecan across all solid tumors, and particularly for patients with CRC with the highest level of expression of HER2, known as IHC3+, has been significant. It complements the tucatinib and trastuzumab regimen from the MOUNTAINEER trial (NCT03043313), which was approved for both IHC2+ and IHC3+ types HER2-positive CRC and showed long term response in IHC2+ disease. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Triumvira Immunologics, Inc
Consulting or Advisory Role – Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda
Research Funding – A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst)
Expert Testimony – Seagen
Travel, Accommodations, Expenses – Seagen
